

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/657,383
		Filing Date	September 8, 2003
		First Named Inventor	Yan Chang
		Art Unit	1623
		Examiner Name	L. C. Maier
Sheet	1	of	2
		Attorney Docket Number	104831-0002-103

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AU	US-5,547,945	08-20-1996	Ye et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ² -Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CE4	Barlogie et al., "Etoposide, Dexamethasone, Cytarabine, and Cisplatin in Vincristine, Doxorubicin, and Dexamethasone-Refractory Myeloma," Journal of Clinical Oncology, Vol. 7, No 10 (1989).			
	CF4	Beika et al. "Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL." Oncogene 20, 2190-2196 (2001).			
	CG4	Bergenheim et al. "Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumors in humans." Br. J. Cancer 67, 358-361 (1993).			
	CH4	Bianco et al. "Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. Clin." Cancer Res. 8, 3250-3258 (Oct. 2002).			
	CI4	Bonavida et al. "Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review)." Int. J. Oncol. 15, 793-802 (Oct. 1999).			
	CJ4	Chauhan et al., "A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells." Cancer Res. 65: (18), (2005)			
	CK4	Christodoulou et al. "Anti-proliferate activity and mechanism of action of titanocene dichloride." Br. J. Cancer 77(12), 2088-2097 (1998).			
	CL4	Citro et al. "c-myc Antisense Oligodeoxynucleotides Enhance the Efficacy of Cisplatin in Melanoma Chemotherapy in Vitro and in Nude Mice." Cancer Res. 58, 283-289 (15 Jan. 1998).			
	CM4	Coqueret, O. "Linking cyclins to transcriptional control." Gene 299, 35-55 (2002).			
	CN4	Elez, R. et al. "Tumor regression by combination antisense therapy against Plk1 and Bel-2." Oncogene 22, 69-80 (2003).			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Used in Lieu of PTO/SB08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/557,383
		Filing Date	September 8, 2003
		First Named Inventor	Yan Chang
		Art Unit	1623
		Examiner Name	L. C. Maier
		Attorney Docket Number	104831-0002-103
Sheet	2	of	2

	CO4	Guess et al., "Modified Citrus Pectin (MCP) Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study." Prostate Cancer and Prostatic Diseases 6:301-304 (2003)	
	CP4	Hayashi et al., "Effects of Daily Oral Administration of Quercetin Chalcone and Modified Citrus Pectin on Implanted Colon-25 Tumor Growth in Balb-c Mice." Alternative Medicine Review 5(6):546-552 (2000)	
	CQ4	Hershberger, P.A. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis." Clin. Cancer Res. 7, 1043-1051 (April 2001).	
	CR4	Imam et al. "Interferon-Alpha Induces bcl-2 Proto-Oncogene in Patients with Neuroendocrine Gut Tumor Responding to its Antitumor Action." Anticancer Res. 17, 4659-4666 (1997).	
	CS4	Liu et al., "Citrus Pectin: Characterization and Inhibitory Effect on Fibroblast Growth Factor - Receptor Interaction." J. Agric. Food Chem. 49:3051-3057 (2001)	
	CT4	Miller et al. "Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Non-Small Cell Lung Cancer." J. Clin. Oncol. 18(6), 1346-1350 (March 2000).	
	CU4	Mizutani et al. "Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin." J. Urology 165, 263-270 (Jan. 2001).	
	CV4	Mohammad et al. "The Addition of Bryostatins 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model." Clin. Cancer Res. 6, 4950-4956 (Dec. 2000).	
	CW4	Pharmaceuticals, Inc. Confidential Private Placement Memorandum, 8/23/2000, pp. 1-63.	
	CX4	Swannie et al. "Protein Kinase C Inhibitors." Curr. Oncol. Reports 4(1), 37-46 (Jan. 2002).	
	CY4	Takenaka et al., "Galectin-3 and Metastasis," Glycoconjugate Journal 19:543-549 (2004)	
	CZ4	Tu et al., "Upregulated Expression of BCL-2 in Multiple Myeloma Cells Induced by Exposure to Doxorubicin, Etoposide, and Hydrogen peroxide Blood." Cancer Letters, Vol. 88, No 5 (1996).	
	CA5	Warfield, P. R. "Adhesion of Human Breast Carcinoma to Extracellular Matrix Proteins Is Modulated by Galectin-3." Invasion Metastasis 17, 101-112 (1998).	

Examiner Signature	/Leigh Maier/	Date Considered	11/03/2008
-------------------------------	---------------	----------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/